The Powerful Case for FDA-Approved Weight Loss Injections

By now, most people have heard of Ozempic, Wegovy, Mounjaro, and Zepbound — the brand-name injectable medications that have transformed how doctors treat obesity and type 2 diabetes. The active ingredients behind these drugs, semaglutide and tirzepatide, mimic hormones that regulate blood sugar and appetite, and their weight-loss results have been nothing short of remarkable. They are also expensive, initially running close to or exceeding $1,000 per month for a single prescription at list price. And when demand exploded, supply couldn't keep up.

That shortage opened a door and a lot of people walked through it without realizing what was waiting on the other side. Compounding pharmacies began offering semaglutide and tirzepatide at a fraction of the cost, sometimes as low as $100 to $300 per month. Weight loss clinics, medspa operators, and even some physicians began prescribing these compounded versions enthusiastically. The pitch was simple: same drug, far less money. What wasn't advertised was just as important and potentially far more dangerous.

How compounding pharmacies got into the GLP-1 business and why it was always on borrowed time

To understand the problem, you need to understand how compounding pharmacies are supposed to work. Compounding is a legitimate, longstanding pharmaceutical practice. It exists to serve patients with specific, individualized needs that commercially available drugs cannot meet. A child who needs a medication in liquid form rather than a pill; a patient with a documented allergy to a particular inactive ingredient; someone who requires a dose that isn't available in any standard formulation. Under normal circumstances, compounding pharmacies are prohibited from simply recreating copies of FDA-approved drugs and selling them at scale.

There is, however, a legal exception. When an FDA-approved drug is on the official drug shortage list, compounding pharmacies are permitted to produce versions of that drug to help fill the supply gap. Semaglutide products (Ozempic and Wegovy) were added to that shortage list in March 2022. Tirzepatide products (Mounjaro and Zepbound) followed in December 2022. For the better part of three years, that shortage designation gave compounders a legal foothold to manufacture and distribute these medications on a massive scale.

The legal window has closed

The FDA declared the tirzepatide shortage resolved on December 19, 2024, and the semaglutide shortage resolved on February 21, 2025. Enforcement deadlines for compounders followed shortly after. As of spring 2025, both medications can only be compounded under very narrow, patient-specific circumstances (not manufactured and distributed at scale as they had been). The loophole, in other words, is gone.

What's important to understand is that the compounding industry's interest in these drugs was never purely about serving patients in need. The economics were extraordinary. Studies estimated that the raw ingredient cost to manufacture a one-month supply of compounded semaglutide was less than $5. Compounders were selling that same month's supply for $100 to $300, still far less than the brand-name price, but with a margin that built an entire industry almost overnight. This was a profit opportunity, not a public health mission.

The ingredient shell game: why compounders started adding vitamins

Here is where things get particularly troubling, and where the line between creative legal strategy and outright deception starts to blur. Federal law prohibits compounders from producing "essentially copies" of commercially available drugs. That's a specific legal term — an essentially identical formulation, same active ingredient, same route of administration, same dose. But if a compounder tweaks the formulation, even slightly, they can argue it is no longer a copy.

This is precisely why many compounded semaglutide and tirzepatide formulations began appearing with added vitamins, most commonly cyanocobalamin (Vitamin B12) and niacinamide (Vitamin B3). The clinical rationale offered to patients was usually that these vitamins help reduce side effects like nausea. There may be some anecdotal support for that claim. But the more legally significant reason, according to FDA enforcement reports, is that the addition of these extra ingredients allows compounders to argue their product is not an essentially identical copy of the FDA-approved drug and therefore falls outside the prohibition.

In other words, the vitamins aren't just a health bonus. They are, at least in part, a legal workaround. The product being injected into your body was engineered with the compounder's regulatory exposure in mind, not your specific medical need. Whether you call that clever or cynical probably depends on whose side you're on. But patients deserve to know that the formulation they're receiving was shaped, at least in part, by liability calculus rather than clinical evidence.

FDA's explicit finding

The FDA has specifically stated that it considers claims that compounded products are "generic versions" or contain the "same active ingredient" as FDA-approved GLP-1 drugs to be false or misleading. The agency issued more than 50 warning letters on this basis in September 2025 alone, targeting companies across the U.S. that were making exactly these marketing claims.

The salt form problem: you might not be getting semaglutide at all

Even if you set aside the added vitamins, there is a more fundamental question about what is actually in compounded GLP-1 products. FDA-approved semaglutide (the active ingredient in Ozempic and Wegovy) is a specific molecular form of the compound. Some compounding pharmacies, however, have been using salt forms of semaglutide, most commonly semaglutide sodium or semaglutide acetate. These are chemically different compounds. They are not the same active ingredient as what is in the approved drugs. And critically, they have not been evaluated by the FDA for safety or effectiveness.

The FDA has explicitly flagged this: patients may believe they are receiving semaglutide when they are, in fact, receiving something that is chemically distinct and entirely unstudied in humans at the doses being used. A significant portion of the bulk semaglutide ingredient imported into the United States for compounding came from Chinese manufacturers. A 2025 Brookings Institution report found that three Chinese firms accounting for 20% of those imports had never been inspected by the FDA, and three others accounting for more than 44% of imports had been cited for violations during inspections.

Contamination risk

Sterile injectable medications must be manufactured in highly controlled environments. Multiple compounding facilities received FDA warning letters after inspections found products were prepared under unsanitary conditions, or that sterility testing had failed.

Unknown ingredients

You may not be receiving the molecule you think you are. Salt forms of semaglutide (sodium, acetate) are chemically distinct from the FDA-approved compound and have no established safety profile.

Dosing errors

Brand-name GLP-1 medications come in pre-filled, calibrated auto-injector pens. Compounded versions require patients to draw medication from a vial into a syringe — a process prone to 5x to 20x overdose errors, according to FDA reports. Although FDA approved GLP-1s now also come in vials.

Potency inconsistency

One FDA warning letter documented a semaglutide compounded product that tested at only 79.9% of its labeled potency. In the same facility, a tirzepatide lot failed sterility testing entirely — and patients were not notified.

Counterfeit products

The FDA has identified outright counterfeit compounded GLP-1 products with false pharmacy information on labels — including pharmacies that do not exist, or that did not actually compound the product in question.

No premarket review

Unlike FDA-approved drugs, compounded products are not reviewed for safety, effectiveness, or quality before reaching patients. What you receive has not been independently verified to work or to be safe.

The doctor's financial incentive — and why it matters

There is one more piece of this picture that patients rarely hear discussed openly: the economics on the prescriber side. Compounded medications, unlike FDA-approved brand-name drugs, are typically cash-pay transactions. They don't run through insurance. That means the clinic or physician prescribing and dispensing them captures the full margin on every vial sold.

Consider the math. Bulk semaglutide ingredient costs less than $5 for a month's supply. A clinic charging patients $250 per month for compounded injections is clearing margins that most medical practices could never achieve through standard, insurance-reimbursed care. Weight loss clinics, medspas, and direct-pay practices built significant revenue streams on exactly this model. The physician who tells you that compounded semaglutide is "just as good" as the real thing may genuinely believe it — or may be telling you the version of the story that supports their business model. Either way, the financial incentive to steer patients toward the compounded product rather than the FDA-approved one is real, substantial, and almost never disclosed.

When the cost of the raw ingredient is under $5 and the patient is paying $250, someone is making an extraordinary margin — and it isn't the patient.

This is not to say that every physician who prescribed compounded GLP-1 medications was acting in bad faith. Many were responding to genuine patient need during a period of severe drug shortages, when the FDA-approved drugs were simply unavailable. But the shortage is over. The legal basis for large-scale compounding is gone. And the question now is whether clinics that built their business model on compounded GLP-1s are genuinely transitioning their patients to safe, approved medications — or looking for new legal workarounds to protect their revenue.

What the FDA-approved versions actually give you

It is worth being explicit about what FDA approval actually means, because it is more than a regulatory stamp. When Novo Nordisk submitted semaglutide for approval as Wegovy, the company provided the FDA with years of clinical trial data involving thousands of patients. The agency independently reviewed that data for evidence of safety and effectiveness. The manufacturing process was inspected. The labeling was reviewed. Post-market surveillance continues after approval, and if safety signals emerge, the FDA can require label updates or additional studies.

None of that exists for a compounded product. The compounder's own quality control — if it exists at all — is all that stands between the patient and a product that is contaminated, underdosed, overdosed, or made from the wrong starting material. FDA inspections of compounding facilities have uncovered facilities where sterility testing was being skipped, where failed tests were being ignored, and where patients were not notified even when quality failures were discovered. These are not theoretical risks. They are documented findings from actual inspections of actual facilities that were supplying actual patients.

The bottom line

Semaglutide and tirzepatide are genuinely effective medications. The clinical evidence behind the FDA-approved versions is real, rigorous, and extensive. For patients who qualify, these drugs can be life-changing. The question has never been whether the drugs work — it is whether what is being sold as a cheaper alternative actually is those drugs, is safe, and is being provided under conditions that protect the patient rather than the provider's profit margin.

The answer, in too many cases, has been no. The compounding industry built around these medications capitalized on a legitimate shortage, but it also used that window to establish cash-pay business models that benefited providers far more than patients. The legal landscape has now largely closed the door on large-scale GLP-1 compounding. But products are still being sold, clinics are still dispensing, and patients are still being told they're getting the real thing at a discount.

If you are currently using a compounded GLP-1 medication, talk to your physician about transitioning to an FDA-approved product. Manufacturer savings programs exist. The real medications are now broadly available. There is no good medical reason to remain on a compounded product and there are several compelling reasons not to. Your health is worth the real thing.

All materials contained in this blog post are for informational purposes only and should not be construed as medical advice. Please consult with your physician concerning any and all medical questions and/or problems.